Cargando…
Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
The development of an effective amphotericin B (AmB) topical formulation to replace the systemically toxic injections currently used in cutaneous leishmaniasis (CL) treatment is challenging due to poor absorption through the skin. Aiming at an effective local chemotherapy, we designed PLGA (poly(lac...
Autores principales: | Sousa-Batista, Ariane J., Pacienza-Lima, Wallace, Ré, Maria Inês, Rossi-Bergmann, Bartira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904829/ https://www.ncbi.nlm.nih.gov/pubmed/31331828 http://dx.doi.org/10.1016/j.ijpddr.2019.06.001 |
Ejemplares similares
-
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019) -
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019) -
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2019) -
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis
por: Sengupta, Ritika, et al.
Publicado: (2019) -
Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)